Vaxcyte Pneumococcal Vaccine Hits Phase 3 Goals to Challenge Pfizer and Merck

By Ed Silverman · STAT News · 2026-10-05

According to reporting from STAT News, Vaxcyte disclosed that its experimental shot VAX-31 successfully met primary endpoints in a late-stage clinical trial. The candidate aims to provide broader protection than current market leaders by targeting 31 different bacterial strains l

According to reporting from STAT News, Vaxcyte disclosed that its experimental shot VAX-31 successfully met primary endpoints in a late-stage clinical trial. The candidate aims to provide broader protection than current market leaders by targeting 31 different bacterial strains l